Among the 104 breast cancer patients, 92 (88.5%) had ER-positive breast cancer, 85 (81.7%) had PR-positive breast cancer, 28 (26.9%) had HER2-positive/equivocal breast cancer, while six (5.8%) had triple negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.